<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[YolTech Therapeutics 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=50174></link><description><![CDATA[YolTech Therapeutics 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Wed, 08 Apr 2026 20:46:15 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2026/02/12_31017998_20260222090708_6711002817.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1029001</link><description><![CDATA[SHANGHAI--(Business Wire/Korea Newswire)--YolTech Therapeutics , a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced positive interim data from an investigator-initiated trial (IIT) of YOLT-202, the Company’s investigational in vivo base editing therapy, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) that demonstrated positi...]]></description><pubDate>Sun, 22 Feb 2026 09:40:00 +0900</pubDate></item><item><title><![CDATA[욜테크 테라퓨틱스, 알파-1 항트립신 결핍증 치료를 위한 YOLT-202에 대한 긍정적인 중간 결과 발표]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1029002</link><description><![CDATA[상하이--(Business Wire/뉴스와이어)--욜테크 테라퓨틱스(YolTech Therapeutics) 가 생체 내 유전자 편집 치료제를 개발하는 후기 임상 단계의 생명공학 기업으로서 오늘, 평가된 환자들 중 35mg 및 45mg 용량 수준에서 긍정적인 안전성과 내약성 및 AAT 수치의 의미 있는 증가를 입증한, 알파-1 항트립신 결핍증(Alpha-1 Antitrypsin Deficiency, AATD) 치료를 위한 임상시험용 생체 내 염기 편집 치료제인 YOLT...]]></description><pubDate>Sun, 22 Feb 2026 09:40:00 +0900</pubDate></item></channel></rss>